Pfizer's Lyrica fails to show post-traumatic nerve pain benefit; FDA approves Lilly lung cancer med Portrazza;

> Pfizer's ($PFE) Lyrica has failed to show benefit in patients suffering from a type of post-traumatic nerve pain in a late-stage study. Report

> The FDA has approved Eli Lilly's ($LLY) Portrazza to treat advanced squamous non-small cell lung cancer. Release

> Mylan has launched Clozapine orally disintegrating tablets--a generic of Jazz Pharmaceutical's ($JAZZ) FazaClo--in the U.S. Release

> The U.K.'s cost effectiveness gatekeepers have recommended two treatments for treating recurrent ovarian cancer, but they've rejected a further three. Report

And Finally... The Gaucher disease treatment market may reach $1.16 billion by 2024, GlobalData predicts. More

Suggested Articles

Novartis is taking its MBC campaign to Instagram with a newly launched video series as part of the five-year “Make Your Dialogue Count” effort.

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.